BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 27756582)

  • 1. Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors.
    Muthukaruppan A; Lasham A; Woad KJ; Black MA; Blenkiron C; Miller LD; Harris G; McCarthy N; Findlay MP; Shelling AN; Print CG
    Clin Breast Cancer; 2017 Apr; 17(2):139-153. PubMed ID: 27756582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha.
    Lin W; Huang J; Liao X; Yuan Z; Feng S; Xie Y; Ma W
    Pharmacol Res; 2016 Sep; 111():849-858. PubMed ID: 27491559
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Mitobe Y; Ikeda K; Suzuki T; Takagi K; Kawabata H; Horie-Inoue K; Inoue S
    Mol Cell Biol; 2019 Dec; 39(23):. PubMed ID: 31501276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen Receptor-α Quantification in Breast Cancer: Concordance Between Immunohistochemical Assays and mRNA-In Situ Hybridization for ESR1 Gene.
    Thomsen C; Nielsen S; Nielsen BS; Pedersen SH; Vyberg M
    Appl Immunohistochem Mol Morphol; 2020; 28(5):347-353. PubMed ID: 30920963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
    Hosey AM; Gorski JJ; Murray MM; Quinn JE; Chung WY; Stewart GE; James CR; Farragher SM; Mulligan JM; Scott AN; Dervan PA; Johnston PG; Couch FJ; Daly PA; Kay E; McCann A; Mullan PB; Harkin DP
    J Natl Cancer Inst; 2007 Nov; 99(22):1683-94. PubMed ID: 18000219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.
    Iwamoto T; Booser D; Valero V; Murray JL; Koenig K; Esteva FJ; Ueno NT; Zhang J; Shi W; Qi Y; Matsuoka J; Yang EJ; Hortobagyi GN; Hatzis C; Symmans WF; Pusztai L
    J Clin Oncol; 2012 Mar; 30(7):729-34. PubMed ID: 22291085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.
    Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK
    BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
    Pentheroudakis G; Kotoula V; Eleftheraki AG; Tsolaki E; Wirtz RM; Kalogeras KT; Batistatou A; Bobos M; Dimopoulos MA; Timotheadou E; Gogas H; Christodoulou C; Papadopoulou K; Efstratiou I; Scopa CD; Papaspyrou I; Vlachodimitropoulos D; Linardou H; Samantas E; Pectasides D; Pavlidis N; Fountzilas G
    PLoS One; 2013; 8(7):e70634. PubMed ID: 23923010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
    Wu JR; Zhao Y; Zhou XP; Qin X
    Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
    Kim C; Tang G; Pogue-Geile KL; Costantino JP; Baehner FL; Baker J; Cronin MT; Watson D; Shak S; Bohn OL; Fumagalli D; Taniyama Y; Lee A; Reilly ML; Vogel VG; McCaskill-Stevens W; Ford LG; Geyer CE; Wickerham DL; Wolmark N; Paik S
    J Clin Oncol; 2011 Nov; 29(31):4160-7. PubMed ID: 21947828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and
    Butler EN; Bensen JT; Chen M; Conway K; Richardson DB; Sun X; Geradts J; Olshan AF; Troester MA
    Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):67-74. PubMed ID: 29133365
    [No Abstract]   [Full Text] [Related]  

  • 12. miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
    Endo Y; Toyama T; Takahashi S; Yoshimoto N; Iwasa M; Asano T; Fujii Y; Yamashita H
    Endocr Relat Cancer; 2013 Feb; 20(1):91-102. PubMed ID: 23183268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiles of progesterone receptor loss in human breast tumors.
    Creighton CJ; Kent Osborne C; van de Vijver MJ; Foekens JA; Klijn JG; Horlings HM; Nuyten D; Wang Y; Zhang Y; Chamness GC; Hilsenbeck SG; Lee AV; Schiff R
    Breast Cancer Res Treat; 2009 Mar; 114(2):287-99. PubMed ID: 18425577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of gene expression induced by siRNA targeting of estrogen receptor alpha in MCF7 human breast cancer cells.
    Luqmani YA; Al Azmi A; Al Bader M; Abraham G; El Zawahri M
    Int J Oncol; 2009 Jan; 34(1):231-42. PubMed ID: 19082494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor alpha (ESR1)-signaling regulates the expression of the taxane-response biomarker PRP4K.
    Lahsaee S; Corkery DP; Anthes LE; Holly A; Dellaire G
    Exp Cell Res; 2016 Jan; 340(1):125-31. PubMed ID: 26712520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.
    Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F
    J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHRNA5 belongs to the secondary estrogen signaling network exhibiting prognostic significance in breast cancer.
    Shehwana H; Keskus AG; Ozdemir SE; Acikgöz AA; Biyik-Sit R; Cagnan I; Gunes D; Jahja E; Cingir-Koker S; Olmezer G; Sucularli C; Konu O
    Cell Oncol (Dordr); 2021 Apr; 44(2):453-472. PubMed ID: 33469842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.
    Alles MC; Gardiner-Garden M; Nott DJ; Wang Y; Foekens JA; Sutherland RL; Musgrove EA; Ormandy CJ
    PLoS One; 2009; 4(3):e4710. PubMed ID: 19270750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
    Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
    Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSF Promotes ER-Positive Breast Cancer Progression via Posttranscriptional Regulation of
    Mitobe Y; Iino K; Takayama KI; Ikeda K; Suzuki T; Aogi K; Kawabata H; Suzuki Y; Horie-Inoue K; Inoue S
    Cancer Res; 2020 Jun; 80(11):2230-2242. PubMed ID: 32213542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.